Clinical review report: Vortioxetine hydrobromide (Trintellix) (Lundbeck Canada Inc.) indication: the treatment of major depressive disorder in adults
The objective of this report was to perform a systematic review of the beneficial and harmful effects of vortioxetine 5 mg, 10 mg, and 20 mg oral tablets for the treatment of Major depressive disorder in adults
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
CADTH
2020, November 2020
|
Edition: | Corrected version with redactions |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of vortioxetine 5 mg, 10 mg, and 20 mg oral tablets for the treatment of Major depressive disorder in adults |
---|---|
Physical Description: | 1 PDF file (181 pages) illustrations |